A Clinical Approach for Wellness with Bioidentical Hormones

Gain insights into bioidentical hormones in a clinical approach and their role in achieving optimal health and wellness.

Abstract

In this educational post, I guide you through a practical, evidence-based pathway for diagnosing and treating hormone insufficiency in women and men, while integrating chiropractic care to optimize outcomes. Drawing on current research and my clinical practice as Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I explain how shifts in estrogen, testosterone, and progesterone affect mood, sleep, pain, body composition, libido, stamina, and cardiometabolic health. I compare delivery methods—pellets, patches, transdermals, injections, and selected oral therapies—highlighting release kinetics, aromatization, DHT conversion, receptor biology, and age-related changes in the HPG axis. I also present structured lab interpretation (including why FSH anchors menopausal assessment), dosing logic for men and women (with microdosing strategies), hematologic safety, and fertility-sparing options such as clomiphene. Throughout, I show how integrative chiropractic care enhances autonomic balance, musculoskeletal function, and inflammatory control—amplifying the benefits of hormone therapy. Clear protocols, stepwise reasoning, and clinical observations from my work at PushAsRx, along with my professional updates, are included to create a readable, patient-centered journey.

Why Symptoms Point Us Upstream To Hormone Signaling

I often meet patients who say, “I feel wired but tired,” “I cannot sleep,” “I’m gaining fat despite effort,” or “my drive is gone.” In women, hot flashes, night sweats, brain fog, vaginal dryness, and fibromyalgia-like pain cluster around declining estrogen and androgen signaling. In men, low libido, reduced stamina, sleep fragmentation, mood irritability, and visceral weight gain frequently track with testosterone insufficiency and altered estradiol balance. These symptoms reflect changes across the hypothalamic–pituitary–gonadal (HPG) axis, autonomic nervous system, mitochondrial function, and inflammatory set points (Santoro et al., 2021; Grossmann & Matsumoto, 2017).

• Women commonly present with:

• • Vasomotor instability (hot flashes/sweats) linked to hypothalamic thermoregulatory shifts as estrogen drops (Rance et al., 2013).
  • Sleep dysregulation, anxiety, and cognitive drift as estrogen’s serotonergic and GABAergic support wanes.
  • Genitourinary symptoms (dryness, dyspareunia) and diminished sexual desire with changes in local tissue trophism.
  • Weight gain via altered insulin sensitivity and leptin signaling.
  • Chronic pain and central sensitization are exacerbated by low estrogen/testosterone.

• Men frequently report:

• • Libido decline, motivation loss, and performance anxiety.
  • Poor recovery, reduced lean mass, and increased fat.
  • Sleep fragmentation and irritability from oscillating androgen/estrogen balance.
  • Metabolic drift with insulin resistance and dyslipidemia.

Treating downstream symptoms alone—sedatives for sleep, SSRIs for mood, analgesics for pain—often yields partial relief. When the primary driver is endocrine, we must correct the signal rather than endlessly chase the echo. Bioidentical estrogen improves vasomotor symptoms and sleep in menopause; physiological testosterone restoration in men supports sexual function, mood, and cardiometabolic health when carefully selected and monitored (Stuenkel et al., 2015; Corona et al., 2020).

Physiology Deep Dive: The Brain, Muscle, Metabolism, and Why Dosing Kinetics Matter

• Estrogen

• • Brain: Estrogen modulates serotonin and GABA, stabilizes hypothalamic KNDy neurons to normalize thermoregulation, and supports synaptic plasticity. Low estrogen increases norepinephrine-driven arousal, fueling night sweats and anxiety (Rance et al., 2013).
  • Vascular and metabolic effects: Estrogen promotes endothelial nitric oxide production, favorable lipid profiles, and insulin sensitivity; loss increases vascular tone variability and central adiposity (Manson et al., 2013).
  • Musculoskeletal: Estrogen influences collagen turnover, ligament/tendon integrity, and nociception.

• Testosterone

• • Brain and behavior: Testosterone supports dopaminergic pathways of motivation, attention, and sexual desire; deficiency correlates with anhedonia and cognitive slowing (Walther et al., 2019).
  • Muscle and recovery: Enhances protein synthesis, satellite cell activation, and mitochondrial function—improving strength and fatigue resistance.
  • Metabolic: Improves insulin sensitivity, reduces visceral adiposity; deficiency associates with metabolic syndrome (Grossmann & Matsumoto, 2017).

• Conversion pathways that shape side effects

• • Testosterone converts to DHT via 5α-reductase and to estradiol via aromatase.
  • Bolus dosing (large peaks) saturates enzymes, transiently elevating estradiol or DHT and increasing the risk of acne, gynecomastia, mood lability, and scalp hair shedding.
  • Therefore, sustained release and dose-splitting are not mere conveniences—they are physiologic strategies to reduce conversion-driven side effects.

Lab Interpretation That Anchors Care: Why FSH Guides Menopausal Status

I rely on outcomes and a core lab set to guide safe, decisive care. In women, FSH is my anchor for menopausal status and therapy response because it integrates dynamic estradiol fluctuations through pituitary feedback (Burger et al., 2007; Santoro et al., 2016).

• Minimum baseline labs:

• • FSH in women; total/free testosterone, SHBG, estradiol as appropriate.
  • CBC, CMP, lipids, A1c/fasting insulin, hs-CRP, thyroid panel.
  • PSA in men per shared decision-making.

• How I use FSH:

• • Persistent elevation with 12 months of amenorrhea confirms menopause.
  • With therapy, a reduction from very high FSH (e.g., 100 IU/L) toward the 20s over time correlates with symptom stabilization.
  • I do not “chase” single estradiol numbers in cycling women. I track FSH trends and clinical outcomes.

This approach prevents overtreatment, aligns with physiology, and focuses us on what matters—patient function and safety (Santoro et al., 2016).

Choosing The Right Modality: Pellets, Patches, Transdermals, Injections, and Oral Options

Each delivery method has a kinetic fingerprint. I match physiology, lifestyle, and risk profile to the modality.

Pellets With Sustained Release: Why They Often Fit Best

Modern pellets engineered with ethylcellulose produce a sustained-release profile and smoother symptom control over months. In my practice:

• Advantages

• • Continuous delivery dampens peaks/troughs that heighten aromatase and 5α-reductase activity.
  • Convenience: Women return ~3–4 times/year; men 2–4 times/year, depending on dose.
  • Orientation and press density matter: Horizontal pressing has yielded more uniform dissolution than vertical pressing, which can dump early and collapse late—creating the “felt great last week, crashed this week” phenomenon.

• Insertion-site comfort

• • Incorporating micro-doses of triamcinolone in pellets has reduced local inflammation and scarring in my experience.
  • Use aseptic technique; treat rare cellulitis medically. Removal is seldom required.

• Why does it fit physiology?

• • Steady levels align with receptor occupancy and hypothalamic feedback, reducing autonomic volatility, mood swings, and conversion spikes.

Transdermal Patches and Creams: Targeted and Systemic Options

• Estradiol patches (plain estradiol, no progestin)

• • Reliable, cardiometabolic-friendly systemic option that bypasses first-pass hepatic metabolism and reduces thrombotic impact vs. oral estrogen (Stuenkel et al., 2015).
  • Dosing: Mid-to-higher ranges often needed in symptomatic women in their 50s; start low and titrate in those 70s–80s (“wake the receptors slowly”).

• Testosterone and DHEA creams

• • Scrotal application in men and labial microdosing in women increase absorption through vascular tissues rich in androgen receptors.
  • Improve local trophism, lubrication, and sexual function; systemic levels may be variable, so I track validated symptom scales and outcomes more than a single serum snapshot.

• Estradiol vaginal creams

• • Excellent for urogenital symptoms and dyspareunia; combine with systemic therapy when indicated.

Injections: Immediate Effects, Higher Volatility

• Men:

• • Testosterone cypionate is commonly started at 100–200 mg weekly; I prefer split dosing (e.g., 50–100 mg twice weekly) to reduce peaks, aromatization, mood swings, and erythrocytosis (Bhasin et al., 2018; Corona et al., 2022).
  • Subcutaneous microinjections offer gentler kinetics and patient autonomy. Slow administration and depot dispersion reduce the formation of nodules.

• Women:

• • I use low-dose strategies (e.g., 10–50 mg/week total), often microdosed daily to minimize peak androgen exposure and reduce risk of acne, hair thinning, and mood volatility. I monitor free T, SHBG, and clinical response (Davis et al., 2019).

Oral and Other Options: Niche Uses and Fertility Considerations

• Oral estradiol can be cost-effective but involves first-pass hepatic metabolism and a distinct thrombotic profile; transdermal or pellet routes are preferred for cardiometabolic safety (Stuenkel et al., 2015).
• Clomiphene in men who desire fertility:

• • Typical starting regimens include 25 mg daily or 50 mg every other day to stimulate LH and endogenous testosterone; efficacy decreases with age as LH signaling wanes.
  • Monitor for visual changes, mood shifts, and biochemical response. Titrate to avoid supraphysiologic estradiol.

---

Modulating Women’s Hormones-Video

---

Progesterone Done Right: Neurosteroid Benefits, Endometrial Safety, and Sleep

Around age 40, many women enter luteal phase insufficiency with steep progesterone drop-offs—fueling heavy, clotty cycles, anxiety, and insomnia. Thoughtful oral micronized progesterone can stabilize cycles and improve sleep:

• Perimenopause

• • I commonly use 100 mg nightly to stabilize neurosteroid effects and endometrial support without cycling due to unpredictable ovulation.
  • Sublingual forms may provide a faster onset for acute anxiety or sleep initiation.

• Postmenopause

• • 200 mg nightly is typical when systemic estrogen is used, and endometrial protection is needed; in older women with increased sensitivity, 100 mg may suffice with careful monitoring.

• Why not rely on progesterone creams for endometrial protection

• • Transdermal absorption is inconsistent; oral micronized progesterone has better evidence for endometrial protection and sleep benefits (The North American Menopause Society, 2022).

Aromatization, Estradiol Balance, and Why Less AI Is Often More

Aromatase converts testosterone into estradiol. Bolus injections foster transient estradiol surges that patients feel as breast tenderness, fluid retention, irritability, or poor sleep. Before reaching for aromatase inhibitors (AIs), I prioritize dose-splitting, microdosing, body composition improvements, and alcohol moderation.

• Why limit routine AI use

• • Estradiol is cardioprotective, supports bone, endothelium, and libido in men; over-suppression can worsen joints, mood, and sexual health (Finkelstein et al., 2013).
  • Smoother kinetics naturally reduce the substrate for the aromatase pathways.

• Clinical approach

• • Check estradiol and SHBG at trough.
  • Adopt twice-weekly or daily microdosing when estrogenic symptoms appear.
  • Use lifestyle levers—resistance training, weight optimization, and reduced alcohol intake—to lower aromatase burden (Corona et al., 2022).

Hematologic Safety and Dosing Kinetics: Preventing Erythrocytosis

Testosterone stimulates erythropoiesis via erythropoietin and marrow signaling. Large boluses increase the risk of elevated hemoglobin/hematocrit. My protocol:

• Baseline CBC; recheck at 6–12 weeks post-initiation and then every 6–12 months (Bhasin et al., 2018).
• Split doses to reduce peaks that drive rapid red cell expansion.
• Address sleep apnea, dehydration, and smoking; titrate dose or consider phlebotomy in select cases.

A steady-state, microdosed exposure leads to gentler hematologic adaptation—and calmer blood pressure and fluid balance.

Transitioning Modalities and Using Boosts: Practical Timelines and Rationale

• From patches to pellets (women)

• • Continue the patch for 3–5 days after pellet insertion to bridge the early ramp; then discontinue to avoid overlap-related side effects.

• From gels/injections to pellets (men and women)

• • Continue the prior modality for about 2 weeks post-insertion to prevent a therapeutic valley. Pellets reach a robust steady state over weeks; the overlap improves continuity.

• Perimenopausal dosing pearls

• • I start low (e.g., a basal ~6 mg estrogen approach) to smooth troughs, respect endogenous ovarian output, and minimize bleeding or breast tenderness.

• Boosts

• • A modest testosterone or estrogen “boost” can close gaps when symptoms persist despite a good base. I only boost if safety labs are clear and symptom clusters justify it; I reassess based on outcomes rather than chasing rapid lab shifts.

Treatment Pathways: A Stepwise, Patient-Centered Workflow

• Assessment and baseline

• • Detailed symptom mapping: vasomotor, sleep, mood, libido, stamina, pain, cognition.
  • Labs: FSH, estradiol, total/free testosterone, SHBG, LH/FSH, DHEA-S, thyroid, insulin/A1c, lipids, hs-CRP, and CBC/CMP.
  • Risk review: thrombotic risk, breast/prostate factors, metabolic syndrome, sleep apnea, mood scales.
  • Fertility goals: clomiphene vs. exogenous testosterone.

• Modality selection

• • Pellets with ethylcellulose for smooth systemic coverage in aromatase-prone or convenience-focused patients.
  • Estradiol patches for systemic estrogen when pellets are not preferred.
  • Labial/scrotal androgen creams for local tissue support and targeted absorption.
  • Split injections or microdosing for fine control; subcutaneous techniques for gentler kinetics.
  • Clomiphene for younger men preserving fertility, with careful monitoring.

• Monitoring and adapting

• • Track validated scales (e.g., Menopause Rating Scale, Aging Male Symptoms Scale), symptoms, and labs.
  • Titrate to outcomes and safety rather than a single lab target.

Integrative Chiropractic Care: The Multiplier For Autonomic, Musculoskeletal, and Metabolic Health

Chiropractic care is a force multiplier for hormone therapy. By improving joint mechanics, myofascial balance, and neural integration, we shift autonomic tone toward parasympathetic dominance, reduce inflammatory signaling, and enable patients to capitalize on hormone-driven recovery and anabolism.

• Autonomic regulation

• • Gentle, well-targeted adjustments and soft-tissue care can reduce sympathetic overdrive, lower nocturnal arousals, and improve sleep—synergizing with estrogen’s thermoregulatory stabilization and testosterone’s restorative effects.

• Pain modulation and central sensitization

• • Hormone optimization reduces hyperalgesia; combined with myofascial release, neural mobilization, and graded movement, patients regain function faster and rely less on analgesics.

• Biomechanical efficiency and mitochondrial support

• • Testosterone enhances mitochondrial biogenesis and protein synthesis; chiropractic-guided corrective exercise and kinetic-chain integration translate these cellular gains into improved posture, strength, and endurance.

• Metabolic benefits

• • Reduced pain enables consistent resistance training, improving insulin sensitivity and body composition—lowering aromatase activity in adipose and improving testosterone-to-estradiol dynamics.

You can explore my case insights and evolving protocols at PushAsRx and my professional updates:

• https://pushasrx.com/
• https://www.linkedin.com/in/dralexjimenez/

Clinical Observations From Practice Patterns That Deliver Wins

From my ongoing clinical work:

• Men and women who adopt twice-weekly injections or daily microdosing report fewer mood swings and steadier libido than those on weekly boluses.
• Perimenopausal women with heavy, clotty cycles often improve within weeks on 100 mg nightly oral micronized progesterone—sleep deepens, anxiety softens, and bleeding normalizes.
• Men with early estradiol-related symptoms improve by smoothing kinetics and optimizing body composition rather than reflexively adding AIs.
• Older adults typically need lower doses—receptor density and sensitivity shift with age; smaller amounts deliver meaningful gains without overshooting.
• Coaching on subcutaneous oil injection technique—slow administration, depot dispersion, site rotation—prevents nodules and improves adherence.

These patterns align with published literature on hormone optimization, sleep, cardiometabolic outcomes, and movement-based care (Stuenkel et al., 2015; Corona et al., 2020; Walther et al., 2019).

Special Scenarios: Fertility, Breastfeeding, Menstrual Migraine, and Medication Strategies

• Fertility preservation (men)

• • Clomiphene stimulates endogenous LH and testosterone secretion, thereby preserving spermatogenesis. Start low; monitor estradiol and symptoms; efficacy declines with age-related changes in LH signaling.

• Breastfeeding

• • Evidence on testosterone transfer to breast milk is limited. I use shared decision-making, lowest effective doses, and careful observation of mother and infant; I avoid initiating androgen therapy without thorough discussion.

• Pregnancy

• • I do not initiate testosterone pellets during pregnancy and halt further insertions if pregnancy occurs; fetal development takes precedence.

• Menstrual migraines

• • Cyclical migraines driven by estrogen withdrawal often respond to a low, steady estrogen baseline that prevents precipitous drops; improvement rates can be striking when the trigger is addressed (MacGregor, 2023).

• SSRI weaning during hormone rebalancing

• • When appropriate, I collaborate with the prescribing clinician and taper slowly to avoid discontinuation syndromes—using every-other-day or dose-halving strategies with frequent check-ins (NICE, 2022). Restored estradiol/testosterone often improves mood and sleep, enabling cautious reduction of SSRIs’ sexual and weight side effects.

• Layering DHEA, thyroid, and GLP-1

• • I optimize sex hormones first to stabilize energy and sleep. Then, one at a time, I layer DHEA, thyroid optimization, or GLP-1 therapy to isolate benefits and avoid attribution errors—especially important when GI side effects could be misattributed to hormone therapy.

Putting It All Together: A Personalized, Physiology-First Plan

• Start with a thorough history, goals, and baseline labs.
• Prioritize FSH for menopausal status; use symptom scales to anchor outcomes.
• Choose the modality that matches physiology and lifestyle:

• • Ethylcellulose-sustained pellets for smooth coverage and convenience.
  • Estradiol patches for systemic estrogen with a favorable safety profile.
  • Labial/scrotal creams for local trophism and sexual function.
  • Split injections and subcutaneous microdosing for kinetic stability.
  • Clomiphene for fertility preservation.

• Integrate chiropractic care for autonomic balance, pain modulation, movement quality, and metabolic gains.
• Monitor CBC, estradiol, testosterone, SHBG, PSA (when appropriate), and inflammatory markers; adjust dosing based on outcomes and safety.
• Consider boosts when partial improvement persists; layer adjuncts (DHEA, thyroid, GLP-1) sequentially.

When we align endocrine kinetics with neuromusculoskeletal care and lifestyle, patients move from volatility to stability—sleep improves, mood steadies, libido returns, pain recedes, and energy rises. This is the essence of integrative, evidence-based hormone optimization.

References

• Bhasin, S., et al. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744.
• Burger, H. G., Dudley, E. C., Robertson, D. M., & Dennerstein, L. (2007). The aging female reproductive axis. Human Reproduction Update, 8(6), 559–565.
• Corona, G., et al. (2020). Testosterone therapy: What we have learned in the last decade. Andrology, 8(4), 1014–1029.
• Corona, G., et al. (2022). Management of estradiol levels in men undergoing testosterone therapy. International Journal of Impotence Research, 34, 236–244.
• Davis, S. R., et al. (2019). Global consensus position statement on the use of testosterone therapy for women. Maturitas, 128, 89–93.
• Finkelstein, J. S., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022.
• Grossmann, M., & Matsumoto, A. M. (2017). A perspective on middle-aged and older men with low testosterone. The Journal of Clinical Endocrinology & Metabolism, 102(3), 1067–1075.
• Hackett, G., et al. (2017). British Society for Sexual Medicine guidelines on adult testosterone deficiency. BJU International, 120(5), 724–734.
• MacGregor, E. A. (2023). Menstrual migraine: Understanding and management. Journal of Neurology, Neurosurgery & Psychiatry, 94(10), 825–832.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368.
• Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 fatty acids and cardiovascular disease. Journal of the American College of Cardiology, 58(20), 2047–2067.
• The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.
• Rance, N. E., et al. (2013). Neurokinin B and hot flushes: Evidence from basic and clinical studies. Menopause, 20(3), 232–238.
• Santoro, N., et al. (2016). Menopause: Hormones, symptoms, and management. Nature Reviews Endocrinology, 12(7), 457–466.
• Santoro, N., et al. (2021). Perimenopause: From research to practice. Journal of Women’s Health, 30(1), 9–18.
• Saad, F., et al. (2017). The effects of testosterone on mood, depression, and well-being in men. Andrology, 5(5), 839–850.
• Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011.
• Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart-brain connection. International Journal of Psychophysiology, 73(3), 202–207.
• Walther, A., et al. (2019). Testosterone, cognition, and emotion: A narrative review. Frontiers in Neuroscience, 13, 740.
• National Institute for Health and Care Excellence. (2022). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management. NICE Guideline NG215.

SEO tags: hormone pellets, sustained-release hormone therapy, ethylcellulose pellets, triamcinolone pellet formulation, estrogen therapy, estradiol patch, testosterone therapy, microdosing testosterone, clomiphene fertility, aromatase management, DHT conversion, oral micronized progesterone, perimenopause progesterone, erythrocytosis safety, integrative chiropractic care, autonomic regulation, pain modulation, sleep optimization, metabolic health, evidence-based hormone therapy, Dr. Alexander Jimenez clinical insights, PushAsRx, FSH menopausal status, menstrual migraine estrogen stabilization